Inhaled interferon for hand, foot, and mouth disease in children
Treatments studied
Part of Infections clinical trials.
This trial tests whether breathing in a medication called pegylated interferon helps children with mild hand, foot, and mouth disease recover faster. It is for children ages 1 to 6 who have had symptoms like fever or rash for 3 days or less.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is 1 to 6 years old
- Has hand, foot, and mouth disease with fever or rash that started within the last 3 days
- Does not have severe symptoms like trouble breathing, confusion, or weakness in the arms or legs
- Has not used certain antiviral drugs or steroids in the past month
- No known allergies to interferon medications
- No serious health problems like heart disease, malnutrition, or immune disorders
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine that targets two viruses causing hand, foot, and mouth disease. It aims to see if the vaccine is safe and effective for people aged 6 months to 59 years.
This study tests an inhaled form of peginterferon alpha-2b for children aged 1 to 3 years who have pneumonia caused by RSV. The goal is to see if this treatment helps them recover faster.
This trial tests a new two-in-one vaccine to protect children against hand, foot, and mouth disease caused by two common viruses (EV71 and CA16). It is for healthy kids ages 6 months to 5 years and will check if the vaccine is safe and works well.
This study simply watches children with hand, foot, and mouth disease or herpangina to learn more about these illnesses. Your child's regular care won't change, and no extra treatments are given.
This study tests a new vaccine that protects against four types of enterovirus (EV71, CA16, CA10, CA6) that cause hand, foot, and mouth disease. Researchers want to see if the vaccine is safe and effective in young children ages 6 months to 6 years.
This trial tests if peginterferon alfa-2b can help children with chronic hepatitis B achieve a functional cure. If your child has had hepatitis B for a while and still has the virus in their blood, this study might be an option.
Hear when a new HFMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.